Purpose: To observe the role of chemotherapy combined with microwave ablation in the treatment of oligometastatic non-small cell lung cancer (NSCLC).
Methods: 68 oligometastatic NSCLC patients were enrolled in this comparative study and randomly received chemotherapy with intermittent CT guided microwave ablation or chemotherapy only. The efficacy and the adverse effects were evaluated at 1, 3, and 6 months after treatment.
Results: Patients in the experimental group received microwave ablation after chemotherapy (n=s34), complete remission (CR) was found in 8 cases (23.53%), partial remission (PR) in 16 cases (47.06%), and the total effective rate (CR+PR) was 70.59%. Microwave ablation with concurrent chemotherapy was performed in patients of the control group (n=33) and there were 0 patients of CR (0%), 12 patients of PR (36.36%), and the total effective rate (CR+PR) was 36.36% (χ2=7.890, p<0.01). The score of Karnofski performance status (KPS) in the experimental group was significantly higher (p<0.05). The median progression-free survival (PFS) in the control group and the experimental group was 3.6±0.2 months and 5.4±0.1 months (χ2=42.731, p<0.01). The incidence of pneumothorax and bloody sputum in the experimental group was higher than that in the control group (χ2=6.031, p<0.05). However, no evident differences were found regarding other common complications of microwave ablation and chemotherapy.
Conclusion: Chemotherapy combined with intermittent microwave ablation is superior to chemotherapy alone in improving the disease control rate and the quality of life of patients, as well as prolonging the PFS of patients.
Download full-text PDF |
Source |
---|
ANZ J Surg
December 2024
Department of Oncology, Leping Traditional Chinese Medicine Hospital, Leping, China.
Background: Both radiofrequency ablation (RFA) and microwave ablation (MWA) are commonly used non-surgical treatment methods for lung cancer/lung metastases (LC/LM). However, there is still debate over which one is superior. The meta-analysis was conducted to evaluate the effectiveness and safety between the two groups.
View Article and Find Full Text PDFAnn Ital Chir
December 2024
Radiotherapy Department, Affiliated Hospital of Hebei University, 071003 Baoding, Hebei, China.
Front Reprod Health
December 2024
Department of Obstetrics and Gynaecology, Fribourg University Hospital, Fribourg, Switzerland.
Adenomyosis is a commonly encountered pathology in women of reproductive age and frequently coexists with infertility. The effect of adenomyosis on fertility, particularly on fertilisation and intracytoplasmic sperm injection outcomes, is not well understood. Various pretreatment modalities have been used to improve pregnancy rates and live birth outcomes; however, because of a lack of high-quality evidence, there is no clear consensus on the best pretreatment option.
View Article and Find Full Text PDFIET Syst Biol
December 2024
Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
Oral squamous cell carcinoma (OSCC) is a common head and neck malignant tumour with high incidence and poor prognosis. Arsenic trioxide (ATO) has therapeutic effects on solid tumours. Microwave ablation (MWA) has unique advantages in the treatment of solid tumours.
View Article and Find Full Text PDFHead Neck
December 2024
Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Background: This study aimed to evaluate the safety, efficacy, and oncologic outcomes of thermal ablation techniques, including radiofrequency, laser, and microwave ablation, in treating primary thyroid cancer compared with surgical resection.
Method: We conducted a systematic review and network meta-analysis, which included 21 comparative studies and 40 noncomparative studies.
Results: The three thermal ablation techniques showed significant superiority over surgical resection in terms of operative time, pain, cost, quality of life, and complications.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!